Frontiers in Oncology (Mar 2022)

Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study

  • Elizabeth M. Corley,
  • Moaath K. Mustafa Ali,
  • Moaath K. Mustafa Ali,
  • Hanan Alharthy,
  • Kathryn A. F. Kline,
  • Kathryn A. F. Kline,
  • Danielle Sewell,
  • Jennie Y. Law,
  • Jennie Y. Law,
  • Seung Tae Lee,
  • Seung Tae Lee,
  • Sandrine Niyongere,
  • Sandrine Niyongere,
  • Vu H. Duong,
  • Vu H. Duong,
  • Maria R. Baer,
  • Maria R. Baer,
  • Ashkan Emadi,
  • Ashkan Emadi,
  • Ashkan Emadi,
  • Ashkan Emadi

DOI
https://doi.org/10.3389/fonc.2022.804961
Journal volume & issue
Vol. 12

Abstract

Read online

Acute myeloid leukemia (AML) is the common type of acute leukemia in adults. Definitive prognostic significance of variants of unknown significance lacks for many commonly mutated genes, including the isocitrate dehydrogenase 1 (IDH1) synonymous single nucleotide polymorphism (SNP) variant c.315C>T. In this retrospective cohort study of 248 AML patients at the University of Maryland Greenebaum Comprehensive Cancer Center, we show that the IDH1 c.315C>T SNP, previously reported to be associated with poor prognosis by other studies with conflicting data, does not confer worse prognosis, with a median overall survival (OS) of 17.1 months compared to 15.1 months for patients without this SNP (P=0.57). The lack of negative effect on prognosis by IDH1 SNP c.315C>T is consistent with the absence of amino acid alteration (p.Gly105Gly).

Keywords